臨床検査58巻1号

2014年01月発行

今月の特集2 深在性真菌症を学ぶ

アスペルギルス症

著者： 武田和明¹ 泉川公一¹ 河野茂¹

所属機関： ¹長崎大学大学院　医歯薬学総合研究科感染免疫学講座（第二内科）

ページ範囲：P.81 - P.89

●侵襲性肺アスペルギルス症（IPA）は免疫抑制患者に好発する．

●慢性肺アスペルギルス症（CPA）は既存の肺疾患の存在する患者に好発する．

●Aspergillus fumigatusは48℃以上でも発育可能であることから鑑別可能である．

参考文献

1）Kume H, Yamazaki T, Togano T, et al：Epidemiology of visceral mycoses in autopsy cases in Japan: comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in Annual of Pathological Autopsy Cases in Japan. Med Mycol J　52：117-127，2011

2）Ali ZA, Ali AA, Tempest ME, et al：Invasive pulmonary aspergillosis complicating chronic obstructive pulmonary disease in an immunocompetent patient. J Postgrad Med　49：78-80，2003

3）Kami M, Tanaka Y, Kanda Y, et al：Computed tomographic scan of the chest, latex agglutination test and plasma (1→3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis : a prospective study of 215 patients. Haematologica　85：745-752，2000

4）Abramson S：The air crescent sign. Radiology　218：230-232，2001

5）Walsh TJ, Anaissie EJ, Denning DW, et al：Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis　46：327-360，2008

6）深在性真菌症のガイドライン作成委員会（編）：深在性真菌症の診断・治療ガイドライン2007，協和企画，2007

7）Smith NL, Denning DW：Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J　37：865-872，2011

8）Denning DW, Riniotis K, Dobrashian R, et al：Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis　37(Suppl 3)：S265-S280，2003

9）Binder RE, Faling LJ, Pugatch RD, et al：Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore)　61：109-124，1982

10）Gefter WB, Weingrad TR, Epstein DM, et al：“Semi-invasive” pulmonary aspergillosis: a new look at the spectrum of aspergillus infections of the lung. Radiology　140：313-321，1981

11）Hope WW, Walsh TJ, Denning DW：The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol　43（Suppl 1）：S207-S238，2005

12）Izumikawa K, Tashiro M, Kohno S, et al：Management of chronic pulmonary aspergillosis. Ann N Y Acad Sci　1272：40-48，2012

13）Tashiro T, Izumikawa K, Tashiro M, et al：A case series of chronic necrotizing pulmonary aspergillosis and a new proposal. Jpn J Infect Dis　66：312-316，2013

14）Tashiro T, Izumikawa K, Tashiro M, et al：Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward. Med Mycol　49：581-587，2011

15）Bašková L, Buchta V：Laboratory diagnostics of invasive fungal infections: an overview with emphasis on molecular approach. Folia Microbiol (Praha)　57：421-430，2012

16）藤内智，山本泰司，武田昭範，他：慢性壊死性肺アスペルギルス症臨床診断例におけるガラクトマンナン抗原およびβ-Dグルカン値の検討．日本呼吸器学会雑誌　47：7-11，2009

17）De Pauw B, Walsh TJ, Donnelly JP, et al：Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis　46：1813-1821，2008

18）Maertens JA, Klont R, Masson C, et al：Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis　44：1329-1336，2007

19）Kitasato Y, Tao Y, Hoshino T, et al：Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology　14：701-708，2009

20）Izumikawa K, Yamamoto Y, Mihara T, et al：Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. Med Mycol　50：811-817，2012

21）Zandijk E, Mewis A, Magerman K, et al：False-positive results by the platelia Aspergillus galactomannan antigen test for patients treated with amoxicillin-clavulanate. Clin Vaccine Immunol　15：1132-1133，2008

22）Mennink-Kersten MA, Ruegebrink D, Klont RR, et al：Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol　43：3925-3931，2005

23）Kami M, Fukui T, Ogawa S, et al：Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis　33：1504-1512，2001

24）Herbrecht R, Denning DW, Patterson TF, et al：Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med　347：408-415，2002

25）Cornely OA, Maertens J, Bresnik M, et al：Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis　44：1289-1297，2007

26）Caillot D, Thiébaut A, Herbrecht R, et al：Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies : a randomized pilot study (Combistrat trial). Cancer　110：2740-2746，2007

27）Regnard JF, Icard P, Nicolosi M, et al：Aspergilloma: a series of 89 surgical cases. Ann Thorac Surg　69：898-903，2000

28）Kohno S, Izumikawa K, Ogawa K, et al：Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect　61：410-418，2010

29）Kohno S, Izumikawa K, Yoshida M, et al：A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis　32：387-397，2013

30）Tashiro M, Izumikawa K, Hirano K, et al：Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus. Antimicrob Agents Chemother　56：4870-4875，2012

31）Tashiro M, Izumikawa K, Minematsu A, et al：Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother　56：584-587，2012